FDA Approval Alert: The Need-to-Know | Mirvetuximab Soravtansine in FRα+ Ovarian Cancer

In March 2024, The FDA granted approval to mirvetuximab soravtansine-gynx as a treatment for patients with folate receptor alpha–positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.
FDA Approves Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Article
Mar 22, 2024 6:53 PM
Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.